Patent ID: 11873339
Assignee: PIERRE FABRE MEDICAMENT
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C

Claim 19:
20. An in vitro method of monitoring a C10orf54-mediated disease comprising:
(a) assaying the level of a human C10orf54 antigen in cells or a tissue sample of a subject using an antibody or antigen-binding fragment thereof, the antibody comprising:
a heavy chain variable domain comprising the following three CDRs, respectively CDR-H1 having the sequence SEQ ID NO: 1302, CDR-H2 having the sequence SEQ ID NO: 1365 and CDR-H3 having the sequence SEQ ID NO: 1402, and
a light chain variable domain comprising the following three CDRs, respectively CDR-L1 having the sequence SEQ ID NO: 1455, CDR-L2 having the sequence SEQ ID NO: 1103 and CDR-L3 having the sequence SEQ ID NO: 1505,

wherein the antibody is conjugated or recombinantly fused to a detectable agent;
(b) comparing the level of the human C10orf54 antigen with a control level of the antigen, wherein an increase in the assayed human C10orf54 antigen level as compared to the control level of the human C10orf54 antigen is indicative of a C10orf54-mediated disease; and
(c) repeating steps (a) and (b) one month, six months, or one year after initial diagnosis of the C10orf54-mediated disease.